RXRX RECURSION PHARMACEUTICALS, INC.

8-K Current Report

Filed: February 25, 2026

Health Care

Biological Products, (No Diagnostic Substances)

RECURSION PHARMACEUTICALS, INC. Overview

RECURSION PHARMACEUTICALS, INC. (RXRX) 8-K current report filed with SEC EDGAR on February 25, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q4 and full-year fiscal 2025 earnings released February 25, 2026
• Full results in Exhibit 99.1 — primary source for revenue, cash position, and pipeline spend details

Item 7.01 · Regulation FD Disclosure

• Recursion released an earnings presentation on Feb 25, 2026 in connection with its Q4/FY earnings call
• Full presentation details in Exhibit 99.2 — key metrics and pipeline updates available there

+1 more insights

Get deeper insights on RECURSION PHARMACEUTICALS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.